Skip to content
Screener

Hemab Therapeutics Holdings, Inc. COAG Price / book

Price / book at other companies

Southern Company logo
Southern CompanySO
2.7×0.0×
Synopsys logo
SynopsysSNPS
3×-3.8×
Northern Trust logo
Northern TrustNTRS
2×+0.5×
Dycom Industries logo
Dycom IndustriesDY
6.6×+2.8×
Nucor logo
NucorNUE
1.8×+0.4×
Semtech logo
SemtechSMTC
17.1×+12.6×

Other financials

Income statement

See full
Operating income-$26.1M-62.4%
Net income-$24.2M-97.8%
EPS (diluted)-$0.80+93.8%

Balance sheet

See full
Cash & equivalents$237.4M—
Total debt$1.0M—
Total equity$454.3M+421%
Total assets$467.8M—

Cash flow

See full
Operating cash flow-$22.6M-47.6%
CapEx$23.0K—
Free cash flow-$22.7M-47.8%

Valuation

See full
Market cap$2.32B+107%
Enterprise value$2.08B—

Returns & leverage

See full
Return on equity-45.7%—
Debt / equity0×—
Current ratio35.8×—

Where this comes from

Calculated from Hemab Therapeutics Holdings, Inc.’s reported figures.

market cap/total stockholders equity=3.8×

Based on the most recent quarter.

The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344533

FAQ

What is Hemab Therapeutics Holdings, Inc.'s price / book?
Hemab Therapeutics Holdings, Inc. (COAG) reported price / book of 3.8× in Q2 2026.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Hemab Therapeutics Holdings, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude